Cigna Group Affirms 2024 Financial Guidance

Ticker: CI · Form: 8-K · Filed: 2024-06-06T00:00:00.000Z

Sentiment: neutral

Topics: guidance-affirmation, financial-results

Related Tickers: CI

TL;DR

Cigna Group confirms 2024 EPS guidance of $25.40-$26.00.

AI Summary

On June 6, 2024, The Cigna Group filed an 8-K to affirm its previously issued financial guidance for the full year 2024. The company reiterated its expectation for Adjusted Earnings Per Share (EPS) to be in the range of $25.40 to $26.00. This affirmation comes as the company continues to operate under its existing business structure.

Why It Matters

This filing reassures investors that Cigna Group is on track to meet its previously stated financial targets for the year, providing stability in its outlook.

Risk Assessment

Risk Level: low — The filing is a routine affirmation of existing guidance, not a change in financial performance or outlook.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose is to affirm the company's previously issued financial guidance for the full year 2024.

What specific financial metric is being affirmed?

The company is affirming its guidance for Adjusted Earnings Per Share (EPS).

What is the affirmed range for Adjusted EPS for 2024?

The affirmed range for Adjusted EPS for the full year 2024 is $25.40 to $26.00.

On what date was this guidance originally issued or last updated?

The filing does not specify the date of original issuance or last update, only that the current guidance is being affirmed on June 6, 2024.

Does this filing indicate any changes to Cigna Group's business operations or strategy?

No, the filing states that the guidance is affirmed as the company continues to operate under its existing business structure, implying no significant changes.

From the Filing

0000950159-24-000212.txt : 20240606 0000950159-24-000212.hdr.sgml : 20240606 20240606061517 ACCESSION NUMBER: 0000950159-24-000212 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240606 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20240606 DATE AS OF CHANGE: 20240606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 241023792 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm THE CIGNA GROUP FORM 8-K The Cigna Group Form 8-K Earnings Affirmation false 0001739940 0001739940 2024-06-06 2024-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares         UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K     CURRENT REPORT   Pursuant to Section 13 or 15(d) of the   Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) June 6, 2024   The Cigna Group   (Exact name of registrant as specified in its charter)   Delaware (State or other jurisdiction of  incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Employer Identification No.)     900 Cottage Grove Road Bloomfield , Connecticut 06002   (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code:   ( 860 ) 226-6000   Not Applicable   (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐               Item 7.01 Regulation FD Disclosure. 2024 Outlook Affirmation   The Cigna Group (the “Company” or “our”) officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2024 consolidated adjusted income from operations on a per share basis of at least $28.40 per share. Additionally, the Company recently completed the

View on Read The Filing